CORRECTION Open Access

## Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation



Ssu-Chuan Lai<sup>1,2</sup>, Yu-Ting Su<sup>1,2,3†</sup>, Ching-Chi Chi<sup>4,5†</sup>, Yung-Che Kuo<sup>1,2,3</sup>, Kam-Fai Lee<sup>6</sup>, Yu-Chih Wu<sup>3,7</sup>, Pei-Chi Lan<sup>3</sup>, Muh-Hwa Yang<sup>8,9</sup>, Te-Sheng Chang<sup>10,11\*</sup> and Yen-Hua Huang<sup>1,2,3,12,13,14,15\*</sup>

## Correction to: J Exp Clin Cancer Res (2019) 38:474 https://doi.org/10.1186/s13046-019-1442-2

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with 'DMT1' now corrected to read 'DNMT1'.

The authors sincerely apologize for the inconvenience caused to the readers.

## **Author details**

<sup>1</sup>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. <sup>2</sup>Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. <sup>3</sup>TMU Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei 11031, Taiwan. <sup>4</sup>Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan. <sup>5</sup>College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan. <sup>6</sup>Department of Pathology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan. <sup>7</sup>School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. 8 Institute of Clinical Medicine, College of Medicine, National Yang Ming University, Taipei 11221, Taiwan. <sup>9</sup>Division of Medical Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan. <sup>10</sup>School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 33382, Taiwan. <sup>11</sup>Division of Internal Medicine, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan. <sup>12</sup>International PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. <sup>13</sup>Center for Reproductive Medicine, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan. <sup>14</sup>Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan. <sup>15</sup>Comprehensive Cancer Center of Taipei Medical University, Taipei 11031, Taiwan

Published online: 13 January 2020

## Reference

 Lai, et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res. 2019;38:474. https://doi.org/10.1186/s13046-019-1442-2.

The original article can be found online at https://doi.org/10.1186/s13046-

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

<sup>\*</sup> Correspondence: cgmh3621@cgmh.org.tw; rita1204@tmu.edu.tw

<sup>&</sup>lt;sup>†</sup>Yu-Ting Su and Ching-Chi Chi contributed equally to this work.

<sup>&</sup>lt;sup>10</sup>School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 33382, Taiwan

<sup>&</sup>lt;sup>1</sup>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan




Fig. 7 IL-6 increases the expression of OCT4 through DNMT3b and IGF-1R activation in human HCC. a Model of how IL-6 increases the expression of OCT4 through p-STAT3-DNMT3b-OCT4-DNMT1 activation in human HCC. b The combination use of nanaomycin and sorafenibsynergistically suppresses the cell proliferation of sorafenib resistant HCC cells